Methylene Blue MMX approved in Europe for the visualization of colorectal lesions during colonoscopies – first oral drug ever approved in the world to improve the outcome of colonoscopies
Cosmo Pharmaceuticals NV today announced that the European Commission (EC) has approved Methylthioninium Chloride Cosmo, prolonged release tablets (Methylene Blue MMX) for the visualization of colorectal lesions during colonoscopies. This is the first approval of Methylene Blue MMX and is also the first time an oral drug has been approved to improve the outcome of colonoscopies. The Centralized European licence will be effective simultaneously in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.